Anna Truini

Anna Truini

Auto-generated profile, based on publicly available information

Anna Truini

Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
SGScott Gettinger
Scott Gettinger
JCJungmin Choi
Jungmin Choi
KHKatherine Hastings
Katherine Hastings
ATAnna Truini
Anna Truini
IDIla Datar
Ila Datar
KPKaterina Politi
Katerina Politi
Mechanisms of acquired resistance to immune checkpoint inhibitors (ICI) are poorly understood. We leveraged a collection of 14 ICI-resistant lung cancer samples to investigate whether alterations in genes encoding HLA Class I antigen processing and presentation machinery (APM) components or interferon signaling play a role in acquired resistance to PD-1 or PD-L1 antagonistic antibodies. Recurrent mutations or copy-number changes were not detected in our cohort. In one case, we found acquired homozygous loss of B2M that caused lack of cell-surface HLA Class I expression in the tumor and a matched patient-derived xenograft (PDX). Downregulation of B2M was also found in two additional PDXs established from ICI-resistant tumors. CRISPR-mediated knockout of B2m in an immunocompetent lung cancer mouse model conferred resistance to PD-1 blockade in vivo, proving its role in resistance to ICIs. These results indicate that HLA Class I APM disruption can mediate escape from ICIs in lung cancer. Significance: As programmed death 1 axis inhibitors are becoming more established in standard treatment algorithms for diverse malignancies, acquired resistance to these therapies is increasingly being encountered. Here, we found that defective antigen processing and presentation can serve as a mechanism of such resistance in lung cancer. Cancer Discov; 7(12); 1420–35. ©2017 AACR. This article is highlighted in the In This Issue feature, p. 1355

23 April 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JRJacqulyne P. Robichaux
Jacqulyne P. Robichaux
YEYasir Y. Elamin
Yasir Y. Elamin
ZTZhi Tan
Zhi Tan
BCBrett W. Carter
Brett W. Carter
SZShuxing Zhang
Shuxing Zhang
JHJohn V. Heymach
John V. Heymach

22 December 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
SDSaravana M. Dhanasekaran
Saravana M. Dhanasekaran
OBO Alejandro Balbin
O Alejandro Balbin
GCGuoan Chen
Guoan Chen
Ernest NadalErnest Nadal
Ernest Nadal
SKShanker Kalyana-Sundaram
Shanker Kalyana-Sundaram
ACArul M. Chinnaiyan
Arul M. Chinnaiyan
Lung cancer is emerging as a paradigm for disease molecular subtyping, facilitating targeted therapy based on driving somatic alterations. Here we perform transcriptome analysis of 153 samples representing lung adenocarcinomas, squamous cell carcinomas, large cell lung cancer, adenoid cystic carcinomas and cell lines. By integrating our data with The Cancer Genome Atlas and published sources, we analyse 753 lung cancer samples for gene fusions and other transcriptomic alterations. We show that higher numbers of gene fusions is an independent prognostic factor for poor survival in lung cancer. Our analysis confirms the recently reported CD74-NRG1 fusion and suggests that NRG1, NF1 and Hippo pathway fusions may play important roles in tumours without known driver mutations. In addition, we observe exon-skipping events in c-MET, which are attributable to splice site mutations. These classes of genetic aberrations may play a significant role in the genesis of lung cancers lacking known driver mutations.

23 July 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Ernest NadalErnest Nadal
Ernest Nadal
ATAnna Truini
Anna Truini
ANAsuka Nakata
Asuka Nakata
JLJules Lin
Jules Lin
RRRishindra M. Reddy
Rishindra M. Reddy
GCGuoan Chen
Guoan Chen
The aim of this study was to identify differentially-expressed miRNAs in the serum of non-small cell lung cancer (NSCLC) patients that might be a clinically-useful tool for lung cancer early detection. We performed miRNA expression profile analysis using TaqMan OpenArray Human panel in a discovery set of 70 serum samples obtained at lung tumor resection and 22 non-cancer subjects (NC). Selected serum miRNAs were then validated by quantitative PCR using an independent validation set of serum samples from LC patients (n = 84) and NC (n = 23). Sixty miRNAs were significantly up-regulated and 31 were down-regulated in the serum from NSCLC patients versus NC (adjusted p < 0.001). Four miRNAs (miR-193b, miR-301, miR-141 and miR-200b) were selected for validating their diagnostic value in an independent cohort. In the discovery set, the ROC plot derived from the combination of these miRNAs yielded an area under the curve (AUC) of 0.985 (95% CI 0.961–1.000, p < 0.001). In the test set, this miRNA signature exhibited an AUC of 0.993 (95% CI 0.979–1.000, p < 0.001). In conclusion, we identified a serum 4-miRNA signature that discriminated with high accuracy lung cancer patients from NC. Further prospective validation of this miRNA signature is warranted.

4 September 2014 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
ATAnna Truini
Anna Truini
AAAngela Alama
Angela Alama
MBMARIA GIOVANNA DAL BELLO
MARIA GIOVANNA DAL BELLO
SCSimona Coco
Simona Coco
IVIrene Vanni
Irene Vanni
FGFRANCESCO GROSSI
FRANCESCO GROSSI
Circulating tumor cells (CTCs) are cells spread from the primary tumor into the bloodstream that might represent an important biomarker in lung cancer. The prognosis of patients diagnosed with lung cancer is generally poor mainly due to late diagnosis. Recent evidences have reported that tumor aggressiveness is associated with the presence of CTCs in the blood stream; therefore several studies have focused their attention on CTC isolation, characterization and clinical significance. So far the CellSearch® system is the only approach approved by FDA for metastatic breast, prostate and colorectal cancer intended to detect CTCs of epithelial origin in whole blood and to assess prognosis. To date no specific biomarkers have been validated in lung cancer and the identification of novel tumor markers such as CTCs might highly contribute to lung cancer prognosis and management. In the present review the significance of CTC detection in lung cancer is examined through the analysis of the published studies in both non-small cell and small cell lung cancers; additionally the prognostic and the clinical role of CTC enumeration in treatment monitoring will be reported and discussed.

15 December 2013 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
Ernest NadalErnest Nadal
Ernest Nadal
GCGuoan Chen
Guoan Chen
MGMarc Gallegos
Marc Gallegos
LLLin Lin
Lin Lin
DFDaysha Ferrer-Torres
Daysha Ferrer-Torres
DBDavid G. Beer
David G. Beer
Purpose: The microRNA-34b/c (miR-34b/c) is considered a tumor suppressor in different tumor types and a transcriptional target of TP53. The main objectives of this study were to investigate the clinical implications of miR-34b/c methylation in patients with early-stage lung adenocarcinoma and to determine the functional role of miR-34b/c re-expression in lung adenocarcinoma cell lines. Experimental Design: Aberrant methylation and expression of miR-34b/c were assessed in 15 lung adenocarcinoma cell lines and a cohort of 140 early-stage lung adenocarcinoma. Lung adenocarcinoma cell lines were transfected with miR-34b/c and the effects upon cell proliferation, migration, invasion, and apoptosis were investigated. Results: Aberrant methylation of miR-34b/c was detected in 6 (40%) of 15 lung adenocarcinoma cell lines and 64 of 140 (46%) primary lung adenocarcinoma. Expression of miR-34b/c was significantly reduced in all methylated cell lines and primary tumors, especially with TP53 mutations. Patients with increased miR-34b/c methylation had significantly shorter disease-free and overall survival as compared to patients with unmethylated or low level of miR-34b/c methylation. Ectopic expression of miR-34b/c in lung adenocarcinoma cell lines decreased cell proliferation, migration, and invasion. Conclusions: Epigenetic inactivation of miR-34b/c by DNA methylation has independent prognostic value in patients with early-stage lung adenocarcinoma. Reexpression of miR-34b/c leads to a less aggressive phenotype in lung adenocarcinoma cell lines. Clin Cancer Res; 19(24); 6842–52. ©2013 AACR.